INTRODUCTION: New drugs have recently been developed, through a better 
understanding of the mechanisms involved in the progression of prostate cancer, 
including castration-resistant ones (CRPC). This article aims to describe the 
mechanisms of action of these new hormonal treatments and their major clinical 
outcomes and development programs.
MATERIALS AND METHODS: A bibliographic research in French and English using 
Medline(®) and Embase(®) using the keywords "castration-resistant prostate 
cancer", "abiraterone acetate", "orteronel", "enzalutamide", and "clinical 
trials" was performed.
RESULTS: the androgen signaling pathway remains the cornerstone of advanced 
cancers management. Hence, some molecules target the androgen biosynthesis, as 
abiraterone acetate and orteronel, which are selective inhibitors of the enzyme 
CYP17. Others act as antagonists of the androgen receptor: the enzalutamide, 
RNA-509 and ODM201. Finally, galeterone combines the two effects.
CONCLUSION: Progress conferred by these molecules in terms of overall survival 
and quality of life in patients with metastatic CRPC, suggest that their use at 
earlier stages of the disease could reduce morbidity and mortality from prostate 
cancer. Determining the best strategy for sequence or combination therapy to 
optimize the use of these new molecules should be investigated.